Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker
Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...
aha.org2h
Report: Prices for top Medicare Part D drugs nearly doubled since entering the market
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, ...
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
Med Device Online8d
5 Reasons Why 2025 Is The Year Pharma Companies Will Revisit Their Drug Delivery Device Strategies
One could be forgiven for feeling the same way about the current world of drug delivery devices, with an increasingly ...
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...
SFGate22d
What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices for everyone
it’s hard to know exactly how much insurers pay for most prescription drugs. This secrecy raises challenging questions. Do PBMs use their size and negotiating power to win lower net prices from ...
Artificial Intelligence in Clinical Trials Market to Hit US$ 2.74 Billion by 2030 with 12.4% CAGR | MarketsandMarkets™.
The global artificial intelligence in clinical trials market , valued at US$1.20 billion in 2023, is forecasted to grow at a ...
The Columbian22d
FDA says knockoff versions of Lilly obesity drug must come off the market
With demand for GLP-1 drugs booming, compounding pharmacies and telehealth companies like Hims and Ro have jumped into the market ... depending on their size, to phase out their products.